Tiagabine
As of the edition of 20 October 2026, Tiagabine is a small molecule: marketed, first approved in 1996 (FR); acts on SLC6A1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1997
- Kind
- Small molecule
- Brand name
- Gabitril
- First approved
- 14 June 1996 (FR)
- Approvals on record
- 10 in 3 regions
- Holder of the most recent approval
- Teva; 3 holders in all
- Registered trials
- 11, 0 stopped early
- Disease areas
- Mental health; Chemically induced; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC6A1 | Sodium- and chloride-dependent GABA transporter 1 | P30531 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 5 | 5 | 0 | 0 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 11 |